In the safety lead-in BEACON CRC trial triple inhibition using a BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and EGFR inhibitor cetuximab was given to BRAFV600E mutation positive patients who had progressed on 1 or 2 prior lines of therapies. This evidence concerns the gene MAP2K7 and colorectal carcinoma.